Azacitidine and Enasidenib for IDH-2 Mutations
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 63 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI), Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- Antimetabolites, IDH2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1555
- NCT Identifier
- NCT03383575
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.